Yahoo
NYSE - Nasdaq Real Time Price USD

Johnson & Johnson (JNJ)

268.73 +2.43 (+0.91%)
At close: October 27 at 4:00:02 PM EDT
265.39 -3.39 (-1.26%)
Pre-Market: 8:57:32 AM EDT
Trade JNJ on Coinbase
Dividend
JNJ announced a cash dividend of $1.34 with an ex-date of Nov. 24, 2026
Chart Range Bar
Loading chart for JNJ

What's happening with JNJ?

5m ago
Powered by Yahoo Scout

Johnson & Johnson’s latest coverage centers on strong growth in Tremfya, encouraging early oncology data, and its long dividend record. Analysts remain divided: growth opportunities support valuation arguments, while patent expirations, competition, and a high earnings multiple create pressure points.

Powered by Yahoo Scout
  • Previous Close 266.30
  • Open 265.25
  • Bid 266.13 x 40000
  • Ask 265.70 x 10000
  • Day's Range 264.83 - 269.09
  • 52 Week Range 184.66 - 281.07
  • Volume 5,762,160
  • Avg. Volume 6,884,589
  • Market Cap (intraday) 646.917B
  • Beta (5Y Monthly) 0.21
  • PE Ratio (TTM) 40.78
  • EPS (TTM) 6.59
  • Earnings Date Oct 13, 2026
  • Forward Dividend & Yield 5.36 (1.99%)
  • 1y Target Est 279.41
  • Morningstar Rating Rating available with Stock Picks access

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

www.jnj.com

138,200

Full Time Employees

December 28

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/27/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

JNJ
31.94%
S&P 500 (^GSPC)
12.81%

1-Year Return

JNJ
44.40%
S&P 500 (^GSPC)
12.33%

3-Year Return

JNJ
100.99%
S&P 500 (^GSPC)
87.56%

5-Year Return

JNJ
88.71%
S&P 500 (^GSPC)
69.66%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 25.4B
Earnings 210M
Profit Margin 0.83%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
5B
10B
15B
20B
25B
5.0%
10.0%
15.0%
20.0%

Analyst Insights

View More

Analyst Price Targets

190.00 Low
279.41 Average
268.73 Current
320.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/16/2026
Analyst Wells Fargo
Rating Action Maintains
Rating Overweight
Price Action Raises
Price Target 275 -> 287

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    16.20%

  • Return on Assets (ttm)

    8.46%

  • Return on Equity (ttm)

    20.02%

  • Revenue (ttm)

    99.33B

  • Net Income Avi to Common (ttm)

    16.09B

  • Diluted EPS (ttm)

    6.59

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    17.23B

  • Total Debt/Equity (mrq)

    54.77%

  • Levered Free Cash Flow (ttm)

    18.5B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: